Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post-Authorisation Safety Study of Esbriet (Pirfenidone): A Prospective Observational Registry to Evaluate Long-Term Safety in a Real-World Setting

Trial Profile

Post-Authorisation Safety Study of Esbriet (Pirfenidone): A Prospective Observational Registry to Evaluate Long-Term Safety in a Real-World Setting

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pirfenidone (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Acronyms PASSPORT
  • Sponsors Roche
  • Most Recent Events

    • 30 Jun 2023 Results of pooled analysis (from studies ASCEND (NCT01366209), CAPACITY 004 (NCT00287716), CAPACITY 006 (NCT00287729), RECAP (NCT00662038), PASSPORT (NCT02699879), and SP-IPF (NCT02951429)published in the Advances in Therapy
    • 12 Sep 2017 Data from this trial was presented at the European Respiratory Society (ERS) congress, according to Roche media release.
    • 12 Sep 2017 Results published in the Roche Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top